



3<sup>rd</sup> March 2020

To,

**BSE LIMITED**

Phiroze Jeejeebhoy Towers  
Dalal Street  
Mumbai - 400001

**THE NATIONAL STOCK EXCHANGE OF INDIA LIMITED**

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block  
Bandra-Kurla Complex, Bandra (East)  
Mumbai - 400051

GlaxoSmithKline Pharmaceuticals Ltd.  
GSK House,  
Dr. Annie Besant Road, Worli,  
Tel No: +91 22 2495 9595  
Fax No: +91 22 2495 9494  
Web: www.gsk-india.com  
Email: askus@gsk.com

Dear Sirs,

**Change in Directorate**

Pursuant to Regulation 30 and Schedule III (A) (7) of the Listing and Disclosure Requirements Regulations, 2015, we wish to inform you that the Board of Directors at its meeting held on 3<sup>rd</sup> March 2020 have approved the following changes in Board of Directors of the Company.

• **Appointment of Mr. Sridhar Venkatesh as a Managing Director**

The Board of Directors of the Company at its meeting held today, has appointed Mr. Sridhar Venkatesh as Managing Director of the Company effective 1<sup>st</sup> April, 2020. He succeeds Mr. Annaswamy Vaidheesh who will retire as a Managing Director from the Company effective 31<sup>st</sup> March, 2020.

**Brief Profile of Mr. Sridhar**

Mr. Sridhar is a senior business leader with more than 24 years of diverse experience in pharmaceuticals & healthcare. He joined GSK in 2011 as Head of Commercial, Established Products, Branded Generics, & Biosimilars and moved as General Manager, Singapore before taking up the role of Commercial Head, India from 2014 to 2016. He was then promoted as VP of Central America & Caribbean before taking the current role as Vice President Emerging Markets East managing direct oversight of six markets (Philippines, Vietnam, Thailand, Malaysia, Indonesia and Srilanka). Sridhar started his career with Eli Lilly and then moved to Pfizer and held increasingly senior roles including the role of Senior Director, Business Development (Asia) for Pfizer before joining GSK. Mr. Sridhar is a Registered Pharmacist, with a Master's in Pharmacy (Pharmaceutical Marketing).

Mr. Sridhar is not related to any of the existing Directors of the Company and he is not debarred from holding the Office of Director by virtue of any order passed by SEBI or any other such authority.

• **Cessation of Ms. Anjali Bansal as Independent Director**

The Board noted that the tenure of Ms. Anjali Bansal on the Board would end effective March 29, 2020 due to completion of her term of 5 years as an Independent Director.

The requisite details as per Regulation 30 are enclosed as Annexure A

Kindly take the above information on record.

Thanking you,

Yours faithfully,

For **GlaxoSmithKline Pharmaceuticals Limited**

Ajay Nadkarni  
Vice President - Administration, Real Estate  
& Company Secretary

**Annexure A**

Sr no	Particulars	Anjali Bansal	Annaswamy Vaidheesh
1	Reason for change viz. appointment, resignation, removal, death or otherwise	<p>Otherwise – Cessation of directorship due to completion of term</p> <p>Ms. Anjali Bansal was appointed as an Independent Director on March 30, 2015 for a term of 5 consecutive years. Accordingly, her tenure shall come to an end on March 29, 2020</p>	<p>Otherwise – Cessation of directorship due to completion of term</p> <p>Mr. Annaswamy Vaidheesh was appointed as Managing Director from 3<sup>rd</sup> August 2015 to 30<sup>th</sup> September 2019. Further he was re-appointed as Managing Director from 1<sup>st</sup> October 2019 for a period of 6 months. Accordingly, his tenure shall come to an end on March 31, 2020</p>
2	Date of appointment / Cessation and term of appointment	Date of cessation – 29 <sup>th</sup> March 2020	Date of cessation – 31 <sup>st</sup> March 2020
3	Brief Profile	Not applicable	Not applicable
4	Disclosure of relationships between directors	Not applicable	Not applicable